 Vascular Biogenics Ltd NASDAQ: VBLT announced positive results of the pre-specified interim analysis of the Phase 3 OVAL study of VB-111 ofranergene obadenovec in recurrent platinum-resistant ovarian cancer. VB-111 ofranergene obadenovec is an anti-cancer gene-therapy. 